Video
22 Oct 2024

Your Molecule. Our Mission.

Watch Video

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.

With over 40 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs.



Content provided by our supplier

Cambrex

  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Service
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Analytical Services
Biopharmaceutical
Chemical Development
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
View company profile

Other Content from Cambrex (5)

  • CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company

    News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company

    After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. 
    16 Jan 2024
  • Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement

    Sponsored Content Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement

    East Rutherford, NJ – May 31, 2023 – Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, yesterday celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, a Belgium-based contract research organization supporting pharmaceutical companies, invitro diagnosis companies, hospitals and universities with analytical services for blood investigations and hemocompatibility testing.
    1 Jun 2023
  • Cambrex Overview Brochure

    Brochure Cambrex Overview Brochure

    Cambrex is an innovative life sciences company with a refreshingly human approach to the way we do business. Our pharmaceutical products, technologies and expertise accelerate your small molecule therapeutics into the market.
  • CPHI North America 2023: from the experts - Cambrex

    News CPHI North America 2023: from the experts - Cambrex

    Throughout CPHI North America (Philadelphia, PA; April 25–27, 2023), we caught up with some of the exhibiting organisations to ask what the show brings to the North American pharmaceutical sector, and what is driving industry innovation in this region of the world.    

    30 May 2023
  • Cambrex Completes Expansion of Snapdragon Chemistry Facility in Waltham, Massachusetts

    News Cambrex Completes Expansion of Snapdragon Chemistry Facility in Waltham, Massachusetts

    East Rutherford, NJ – May 16, 2023 – Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that Snapdragon Chemistry has completed the second phase of its 51,000 square-foot expansion in Waltham, Massachusetts.
    18 May 2023